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ABSTRACT
Type 2 diabetes (T2D) increases the risk for cerebrovascular disease (CVD) and dementia.
The underlying molecular mechanisms remain elusive, which hampers the development of
treatment or/and effective prevention strategies. Recent studies suggest that dyshomeostasis
of amylin, a satiety hormone that forms pancreatic amyloid in patients with T2D, promotes
accumulation of amylin in cerebral small blood vessels and interaction with Alzheimer's
disease (AD) pathology. Overexpression of human amylin in rodents (rodent amylin does not
form amyloid) leads to late-life onset T2D and neurologic deficits. In this Review, we discuss
clinical evidence of amylin pathology in CVD and AD and identify critical characteristics of
animal models that could help to better understand molecular mechanisms underlying the
increased risk of CVD and AD in patients with prediabetes or T2D.
Keywords: Type 2 diabetes mellitus; Diabetes complications; Cerebrovascular disease;
Dementia; Alzheimer's disease; Amyloid

INTRODUCTION
Cerebrovascular disease (CVD) and Alzheimer's disease (AD) are common causes of
dementia.1 The pathological characteristics of CVD include structural and functional
changes in the vasculature that affect oxygen and nutrient delivery to the brain.2 Several risk
factors contribute to the development of CVD, including diabetes, obesity, hypertension
and smoking.3 CVD and cognitive decline have been increasingly recognized as diabetic
complications.4,5 Despite recent advances in the care of patients with Type 2 diabetes (T2D),
the risk of CVD and dementia remains higher (up to 2-fold) in the population with T2D or
prediabetes compared to metabolically normal individuals.6,7 The causative mechanisms
underlying diabetes-associated cognitive dysfunction and dementia remain elusive. Clinical
evidence indicates that overt hyperglycemia is linked to diabetes-associated cognitive decline8
and dementia risk in non-diabetic individuals.9 Multi-centered, randomized controlled
studies have shown, however, that stringent control of glycemic parameters, i.e., glycated
hemoglobin (hemoglobin A1c) and fasting plasma glucose levels, does not improve cognitive
function,10,11 rather, it increased mortality in patients with dementia.11 On the other hand,
repeated hypoglycemic episodes are clearly linked to cognitive decline and increased
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dementia risk.8,12 From these studies, we foresee a need to identify novel contributing factors
to the risk of cognitive impairment in humans with T2D or prediabetes.
Amylin, also known as islet amyloid polypeptide (IAPP), is a hormone co-synthesized
with insulin by pancreatic β-cells and participates in the central regulation of satiety.13
Individuals with prediabetic insulin resistance have hypersecretion of both insulin and
amylin.13 Thus, hyperamylinemia coincides with hyperinsulinemia and prediabetic insulin
resistance, always.
Recent studies show that amylin accumulates in the cerebral small vessels of patients
with dementia and T2D.14,15 Amylin deposition and mixed amylin-β amyloid (Aβ) plaques
were also detected in brains of T2D patients with pathological AD.15,16 These results14-16
suggest a pathological role of amylin dyshomeostasis in the development and progression
of CVD and dementia. Here, we review clinical evidence of amylin pathology in CVD and
dementia, discuss currently available animal models for diabetes and dementia, identify
existent challenges and suggest future work that could lead to uncovering novel molecular
mechanisms underlying the impact of diabetes on brain function.

PERIPHERALLY-MEDIATED AMYLIN DYSHOMEOSTASIS
PROVOKES CEREBRAL SMALL VESSEL DISEASE
Amylin is synthesized and co-secreted with insulin by the pancreatic β-cell.13 The amylin
peptide crosses normally the blood-brain barrier (BBB)17 and binds to neurons in the cerebral
feeding centers to regulate satiety.18,19
Amylin from several mammalian species, including humans, cats, dogs, and monkeys
(but not rodents), forms amyloid when overexpressed.13 Most of the patients with T2D
(>90%) have amylin amyloid deposition in the pancreatic islets.13,20-23 Aggregated amylin
induces β-cell dysfunction and apoptosis, contributing to the gradual loss of β-cell mass.23
Recent studies report that patients with T2D have abnormal accumulation of aggregated
amylin in extra-pancreatic tissues, including the kidneys24 and the heart.25 Accumulating
evidence indicates that the presence of amylin deposition in brains of patients with T2D
and dementia.14-16,26-29 Amylin accumulation is particularly abundant in the cerebral small
vessels.14,15 We showed that microvascular amylin accumulation is associated with infarction
and perivascular astrocyte recruitment, indicative of microvascular injury.14 Schultz et al.27
showed that amylin forms intracellular inclusions in the brain microvascular pericytes of
AD patients with T2D. Amylin-containing pericytes showed fragmented nuclei and loss of
neuron-glial antigen 2 expression, which is necessary for pericyte viability and function.27
Additionally, amylin appears to modulate pericyte autophagy and induces higher toxicity
compared to Aβ amyloid in vitro.27 Results from the same research team showed the presence
of aggregated amylin in the retinal microvessels.29 Capillary amylin accumulation in the
retina appears to correlate with hippocampal amylin angiopathy and amylin burden.29 These
results14-16,27-29 suggest the possibility of using peripherally-mediated amylin dyshomeostasis as
a biomarker of cerebrovascular risk in patients with T2D.
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AMYLIN DYSHOMEOSTASIS AS A CONTRIBUTING
FACTOR TO NEURODEGENERATION
One potential mechanism underlying vascular contributions to cognitive impairment
and dementia (VCID) involves the interaction of diabetes-related amylin dyshomeostasis
with AD pathology (Fig. 1). A study by Westermark et al.13 shows that the level of amylin is
increased in the diffuse and dense cerebral plaques and within vascular amyloid deposits in
brains of patients with pathological AD, without the clinical diagnosis of T2D.16 The results
are consistent with previous data showing that ex vivo cross-seeding by amylin aggregates
exponentially promote mixed amylin-Aβ amyloid formation.16 In line with these findings,
a recent study demonstrates that mice expressing a mutated form of the amyloid precursor
protein (APP) in neurons and human amylin in the pancreatic islets develop mixed amylinAβ plaques in the brain,30 similar to the pathology observed in individuals with T2D and
AD.15,16 When compared to transgenic mice expressing only the human amylin or the
mutated form of APP protein alone, mice with mixed amylin-Aβ pathology show accelerated

Cerebral small
vessels injury

Mixed amylin-Aβ
plaques

Aβ

Brain

Peripherally-mediated
amylin dyshomeostasis

Blood vessel
Release of
pancreatic amylin
Pancreatic amylin

Pancreatic β-cells
Fig. 1. Diabetes-related amylin dyshomeostasis leads to the formation of pancreatic amyloid and promotes
amylin accumulation in the peripheral circulation. Circulating oligomerized amylin deposits in the brain
microvasculature and induces small vessels injury by deranging the microvascular endothelium. Oligomerized
amylin also forms mixed amylin-Aβ plaques in the brain parenchyma, accentuating neurotoxicity. Diabetesrelated amylin dyshomeostasis promotes a feed-forward pathological process by which circulating oligomerized
amylin injures brain microvasculature and synergizes with Aβ pathology to induce dementia.
Aβ, β amyloid.
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neurological dysfunction.30 The mechanism for exacerbated neurological function in this
mice model is postulated due to the increased Aβ burden in association with elevated amylin
accumulation in the brain.30 In contrast, the clinical data shows that Aβ burden is not
increased in patients with T2D and AD.31,32 Thus, further investigations will be necessary to
clarify the specific mechanism(s) underlying the effects of amylin dyshomeostasis on the
brain in humans.
The increased propensity of amylin and Aβ to interact may be due to the fact that the
amino acid sequence of human amylin is 52% similar to that of Aβ1-40 and Aβ1-42. The studies
mentioned in above demonstrate the Aβ-seeding ability of human amylin in the brain.
Nonetheless, one cannot exclude that the Aβ-seeding for amylin deposition is also a possible
process that may occur parallel or independent from amylin-seeding Aβ.
In addition to protein-protein interaction, intriguingly, amylin and Aβ interaction are
also found at the genetic level. Genome-wide association analysis further supports the
interaction between the amylin gene and AD pathophysiology.33 Specifically, near genomewide significant interaction effect was observed for an imputed variant rs73069071, located
on chromosome 12p 12.1, within the amylin gene.33 The rs73069071-by-Aβ deposition
was found for interaction effect on global cognitive function in AD patients.33 Although
remaining elusive, the postulated mechanism involves the effect of this single nucleotide
polymorphism on amylin production, whose product is known to interact with Aβ or
possibly altering Aβ metabolism, hence modulating the impact of Aβ-deposition on
cognitive performance.
Within the effort to understand the interaction of amylin and Aβ pathology, results from
several studies suggest that the interaction is mediated through amylin receptors.34,35
Experimental data suggest that Aβ directly activates amylin receptors, and that the
oligomerized Aβ-induced neurotoxicity can be blocked with specific amylin receptor
antagonists or downregulation of amylin receptor expression.34,35 Interestingly, amylin
receptor expression in the brain was up-regulated within the area of increased amyloid
burden in AD transgenic mice which overexpress the mutated form of APP.35 Thus, while
amylin accumulation appears to have deleterious effects, overexpression of amylin receptor
(by the unknown mechanisms) possibly provides a platform for Aβ-induced neurotoxicity.
Besides pathological interaction of amylin with Aβ, aggregated amylin itself is neurotoxic.
Several mechanisms of amylin-induced neuronal toxicity, including calcium dysregulation,
oxidative stress, and mitochondrial dysfunction have been proposed.28,34,36 In neurons, amylin
forms adduct with 4-hydroxynonenal, a marker of peroxidative membrane injury, leading to
increased synthesis of the pro-inflammatory cytokine interleukin 1β.28 The amylin-mediated
neuronal injuries were blocked ex vivo by membrane stabilizers and lipid peroxidation
inhibitors.28 Thus, aggregated amylin deranges the lipid membrane and predisposes it to
peroxidative injury and inflammatory responses.
Given the pathological function of aggregated amylin,14,15,37 the interaction of amylin with Aβ
may accentuate neurotoxicity. Therefore, prevention strategies to effectively block amylinmediated neurodegeneration should involve the inhibition of amylin-induced neuronal
membrane injury and amylin-Aβ interaction.
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ANIMAL MODELS FOR CONTRIBUTIONS OF T2D TO
COGNITIVE IMPAIRMENT AND DEMENTIA
Rodents are the most commonly used laboratory models for diabetes and dementia owing to their
99% similarity to the human genome.38 However, neither diabetes nor dementia-like pathology
spontaneously occurs in rodents. Conditions associated with diabetes, dementia, or both can
be induced in rodents.14,37,39-41 For the most part, insights from these interventions have been
restricted to cerebral effects of inducing diabetes in normal rodents and in rodents genetically
modified to develop neurodegeneration linked to the accumulation of Aβ in the brain.
In humans with T2D, the variation in the clinical phenotype of cognitive dysfunction or dementia
may result from multiple pathologies.31,42 An existent challenge of using rodent models to
uncover mechanisms underlying the impact of T2D on brain structure and function lies on
the fact that some genetic modifications that lead to T2D phenotype directly impact brain
structure and function. For example, leptin or leptin-receptor deficiency, which is the commonly
used genetic modification to induce obesity-related metabolic disturbances in rodents,43 has
negative effects on learning and memory.44 Thus, interpretations made on specific molecular
mechanisms of diabetes-induced brain dysfunction need careful consideration.
Overexpression (3-fold) of human amylin in rats leads to the mid-life onset of hyperglycemia
linked to pancreatic amylin amyloid and β-cell apoptosis.45 Diabetes in human amylin
expressing rats (HIP rats) is associated with neurological deficits including declined learning
and memory, vestibulomotor dysfunction, altered balance and gait abnormalities.14,37 In
brains of the HIP rats with motor abnormalities, amylin deposition in small blood vessels
correlates with microhemorrhages, decreased tight junction proteins levels and perivascular
astrocyte activation,14 indicating that systemic amylin dyshomeostasis damages the BBB.
Magnetic resonance imaging of HIP rat brains shows increased ventricular volumes with
white matter hyperintensities and brain atrophy.14 Further assessment of cerebral blood
flow in HIP rats via intravenous infusion of fluorescent microspheres and the measurement
of the level of fluorescent microspheres retrieved from the brain capillaries reveal that
amylin dyshomeostasis is associated with capillary loss and decreased cerebral perfusion.14
Amylin dyshomeostasis occludes or/and damages the brain small vessels, leading to brain
parenchymal loss. Therefore, the animal model with amylin dyshomeostasis has the
advantage to recapitulate major lesions, vascular lesion and brain atrophy, seen in brains of
individuals with T2D (; for a review31).

CURRENT CHALLENGES AND FUTURE DIRECTIONS FOR
LABORATORY STUDIES
Investigations of human brain tissues and rodent models for T2D suggest that amylin
dyshomeostasis could play a potential role in the development of CVD and AD in individuals
with T2D. Because amylin is produced in the pancreas and accumulates in the brain in
association with CVD and AD, it is of clinical interest to decipher the central aspects of
amylin dyshomeostasis in diabetes-related CVD and dementia. First, cerebrovascular
accumulation of amylin may require carrier(s) in the circulation. The possible carrier could
be macro-/micro-molecules or cellular components in the circulation. The animal model
for amylin dyshomeostasis discussed above serves as a useful tool for extensive in vivo
characterization of pharmacological interventions. Second, the translocation of amylin
https://e-jla.org
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from the blood vessels to the parenchyma may require protein transporter(s). Likely, such
translocation is concentration-dependent, because high aggregated amylin concentration
is found to directly induce endothelial apoptosis in our previous study.14 Following the
assessment of the cerebrovascular injury in the animal model of amylin dyshomeostasis,
in vitro studies designed to identify specific protein transporter(s) are an important step to
decipher how amylin interacts with BBB units and its translocation mechanism(s). Third, the
specific function of amylin and aggregated amylin in vascular, neuronal and glial cells have
not been fully understood. From our previous studies, we found that aggregated amylin could
directly participate in cerebrovascular injury14 and neurodegeneration.28 However, much less
is known about the effects of aggregated amylin on vascular, neuronal and glial function.
Finally, we propose that understanding the pathways for aggregated amylin clearance from
the circulation and the brain vasculature could be beneficial for therapeutic development.
Indeed, future research should take into consideration that the pathophysiology of T2D
involves a complex interaction of multiple deficiencies. Therefore, the multi-facets of the
T2D requires research models that can represent the complexity of the disease, in order to
understand the underlying mechanisms attributed to CVD or dementia.

CONCLUSION
Diabetes-related amylin dyshomeostasis has a pathological role in CVD and dementia.
Existent evidence has suggested that the accumulation of aggregated amylin in the brain
blood vessels and brain parenchyma, mediated by peripheral amylin dyshomeostasis, is a
potential mechanism underlying VCID.
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